530.19  -8.04 (-1.49%)		07-13 16:00
Open: 527.275 High: 544.418 Volume: 261,761		Pre. Close: 538.23 Low: 523.995 Market Cap: 15,142(M)

Short term
Mid term
Targets	6-month :	663.31	1-year :	774.75
Resists	First :	567.9	Second :	663.31
Pivot price	526.73
Supports	First :	490.68	Second :	442.95
MAs	MA(5) :	536.29	MA(20) :	510.73
	MA(100) :	466.97	MA(250) :	502.25
MACD	MACD :	22.1	Signal :	22.7
%K %D	K(14,3) :	72.7	D(3) :	73.9
RSI	RSI(14): 60.1
52-week	High :	628.91	Low :	306.7

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MEDP ] has closed below upper band by 47.5%. Bollinger Bands are 23.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	545 - 548.13	548.13 - 550.95
Low:	516.94 - 520.28	520.28 - 523.3
Close:	524.64 - 530.02	530.02 - 534.89

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Mon, 13 Jul 2026
Medpace Holdings, Inc. (MEDP) Stock Analysis: Is the Current Valuation Justified Amidst Strong Revenue Growth? - DirectorsTalk Interviews

Sat, 11 Jul 2026
Medpace Holdings (MEDP) Rallies As A More Cautious Narrative Questions The Valuation - Yahoo Finance

Fri, 10 Jul 2026
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Tue, 07 Jul 2026
A Look at Medpace Holdings Inc (MEDP) After 3.4% Decline -- GF V - GuruFocus

Mon, 06 Jul 2026
Medpace: The Recovery Narrative Looks Premature (NASDAQ:MEDP) - Seeking Alpha

Mon, 06 Jul 2026
Medpace Stock Outlook Turns on Backlog Quality and Cancellations - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	29 (M)
Shares Float	23 (M)
Held by Insiders	19.4 (%)
Held by Institutions	87.3 (%)
Shares Short	2,130 (K)
Shares Short P.Month	2,050 (K)

EPS	15.88
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	20.95
Profit Margin	17.1 %
Operating Margin	20 %
Return on Assets (ttm)	17.4 %
Return on Equity (ttm)	77.2 %
Qtrly Rev. Growth	26.5 %
Gross Profit (p.s.)	67.57
Sales Per Share	93.83
EBITDA (p.s.)	20.69
Qtrly Earnings Growth	16.6 %
Operating Cash Flow	739 (M)
Levered Free Cash Flow	491 (M)

PE Ratio	33.34
PEG Ratio	3.2
Price to Book value	25.27
Price to Sales	5.64
Price to Cash Flow	20.45

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.